The White House has withdrawn Dr. Heidi Overton's nomination to be commissioner of the Food and Drug Administration, a senior administration official told CBS News, just as the Senate Health, Education, Labor and Pensions Committee was preparing to vote on her Wednesday. Whip efforts to line up Republican votes were still underway when the administration told allies of its decision Tuesday evening.
Overton, a physician and White House domestic policy staffer, was tapped over the summer. She struggled to win over some Republicans and administration allies, partly over her testimony on the FDA-approved abortion pill mifepristone.
Cassidy: "Viable confirmation path" abandoned
Sen. Bill Cassidy of Louisiana, the outgoing HELP Committee chairman, disputed that Overton lacked support. "Tonight, the White House abandoned a viable confirmation path for Dr. Overton," he said, adding that pro-life senators had sought "final assurances" from the administration on its commitment to life issues. "I believe she would have had the votes to pass out of committee and pass the full Senate," Cassidy said.

The agency, which regulates products accounting for about a fifth of U.S. consumer spending, has lacked a Senate-confirmed leader since Dr. Marty Makary's departure and is run by acting Commissioner Kyle Diamantas. Sources told CBS News the White House has discussed other candidates, including some who could serve in an acting role without Senate confirmation. Sen. Roger Marshall of Kansas, a doctor who lost his reelection bid this month, is said to be seeking the post.
Clock ticking before January
Any Senate-confirmed nominee would have to clear the chamber in the short window before Democrats take control in January. "With the limited time left, confirming a permanent FDA Commissioner will fall to Senate Democrats," Cassidy said, warning that a string of acting chiefs would have less independence from Health Secretary Robert F. Kennedy Jr.
Photos: Getty Images; Jonathan Ernst/Reuters.